Michael Kauffman, Chief Executive Officer at Karyopharm Therapeutics Inc. (KPTI), sold 4,000 shares at $12.39 ($50K) on 2021-03-18, disclosed to the SEC on 2021-03-23.
Scheduled sale ($50k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| KPTI | SELL | 2022-03-02 | $128K | — | Filing → |
| KPTI | SELL | 2022-02-22 | $440K | — | Filing → |
| KPTI | SELL | 2022-02-09 | $266K | — | Filing → |